We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Stan Lipkowitz, MD, PhD, chief of the women's malignancies branch in the National Cancer Institute's Center for Cancer Research, discusses new research into targeting protein degradation.
"One of the reasons this is so exciting is, generally, for small molecule inhibitors, we look for things that have catalytic active sites, so if you want to hit a kinase you can use a small molecule inhibitor,” Lipokowitz said. “The problem is there are many proteins where there is not a catalytic domain that you can inhibit; these include transcription factors or other structural proteins. By using the targeted protein degradation, you can start to address them.”